文献速递腹部技术与安全CTMR

CT与MRI肝脏影像报告和数据系统2018版对肝细胞癌的诊断:系统评价与Meta分析

CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
PubMed 文献 · J Am Coll Radiol · 2020-07-05

该系统评价与Meta分析纳入14项研究、2708个观察灶(其中1841个为肝细胞癌),评估LI-RADS 2018版LR-5类诊断肝细胞癌的效能及各LI-RADS类别中肝细胞癌的合并比例。LR-5类的合并敏感度为70%、特异度为91%;LR-3至LR-5类别中肝细胞癌比例依次升高,各LI-RADS类别间肝细胞癌比例存在显著差异(P=0.022)。

要点

  • LR-5类诊断肝细胞癌的合并敏感度为70%(95%CI 61%-78%),合并特异度为91%(95%CI 89%-93%)。
  • LR-5类中肝细胞癌的合并比例为95%(95%CI 93%-96%),LR-4类为64%(95%CI 47%-80%),LR-3类为31%(95%CI 12%-50%)。
  • LR-1与LR-2类未报告肝细胞癌;各LI-RADS类别间肝细胞癌比例存在显著差异(P=0.022)。

核心结论

  • LI-RADS 2018版LR-5类诊断肝细胞癌具有中等敏感度和高特异度;从LR-3到LR-5,类别越高,所含肝细胞癌的比例越大。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Embase和Scopus数据库自建库至2019年12月7日,最终纳入14项报告LI-RADS 2018版诊断肝细胞癌准确性的研究。
  • 共纳入2708个观察灶,其中1841个为肝细胞癌;采用QUADAS-2工具评估偏倚风险与适用性关切,并使用随机效应模型进行合并估计。

诊断标准与关键数值

  • LR-5类诊断肝细胞癌的合并敏感度为70%(95%CI 61%-78%),合并特异度为91%(95%CI 89%-93%)。
  • LR-3类中肝细胞癌的合并比例为31%(95%CI 12%-50%),LR-4类为64%(95%CI 47%-80%),LR-5类为95%(95%CI 93%-96%)。
  • LR-TIV类中肝细胞癌的合并比例为54%(95%CI 30%-77%),LR-M类为33%(95%CI 21%-46%)。
  • LR-1与LR-2类未报告肝细胞癌;各LI-RADS类别间肝细胞癌比例存在显著差异(P=0.022)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to determine the diagnostic performance of the LR-5 category for hepatocellular carcinoma (HCC) and the pooled proportion of HCC in each Liver Imaging Reporting and Data System (LI-RADS) category with CT and MRI, using LI-RADS version 2018.

METHODS: The MEDLINE, Embase, and Scopus databases were searched from inception to December 7, 2019, for studies reporting the diagnostic accuracy of LI-RADS version 2018 for HCC. Risk for bias and concerns regarding applicability were assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Random-effects models were used to determine the summary estimates of the diagnostic performance of LR-5 and the pooled proportion of HCC for each LI-RADS category.

RESULTS: Fourteen studies were included in the final analysis, consisting of 2,708 observations with 1,841 HCCs. The pooled per-observation sensitivity and specificity of the LR-5 category for diagnosing HCC were 70% (95% confidence interval [CI], 61%-78%) and 91% (95% CI, 89%-93%), respectively. No HCCs were reported for LR-1 and LR-2. The pooled proportions of HCC were 31% (95% CI, 12%-50%) for LR-3, 64% (95% CI, 47%-80%) for LR-4, 95% (95% CI, 93%-96%) for LR-5, 54% (95% CI, 30%-77%) for LR-TIV, and 33% (95% CI, 21%-46%) for LR-M. The proportions of HCC were significantly different among the LI-RADS categories (P = .022).

CONCLUSIONS: The LR-5 category of LI-RADS version 2018 provided moderate sensitivity and high specificity for diagnosing HCC. Higher LI-RADS categories from LR-3 to LR-5 included greater proportions of HCC.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Lee S, Kim YY, Shin J, et al. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. J Am Coll Radiol. 2020. PMID: 32640250. doi:10.1016/j.jacr.2020.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。